Biora-tm_rgb.jpg
Biora Therapeutics to Report First Quarter 2024 Financial Results and Provide Corporate Update
May 07, 2024 08:00 ET | Biora Therapeutics, Inc.
The company’s management will host a webcast and conference call on Wednesday, May 15, 2024, after the close of financial markets.
Biora-tm_rgb.jpg
Biora Therapeutics to Present Clinical Data on Device Function of the NaviCap™ Oral Delivery Platform at Digestive Disease Week 2024
May 06, 2024 08:00 ET | Biora Therapeutics, Inc.
Results of human device function studies for the NaviCap™ Targeted Oral Delivery Platform in healthy volunteers and patients with UC
Biora-tm_rgb.jpg
Biora Therapeutics Announces Completion of Multiple-Ascending Dose (MAD) Cohorts for Clinical Trial of BT-600
April 30, 2024 08:00 ET | Biora Therapeutics, Inc.
Dosing of all patients in the trial has been successfully completed; final results are expected to be available in late Q2 2024.
Biora-tm_rgb.jpg
Biora Therapeutics Announces New Patent Covering its BioJet™ Liquid Jet Delivery Technology
April 08, 2024 08:00 ET | Biora Therapeutics, Inc.
Patent claims cover key jet parameters for liquid jet delivery of a drug to the gastrointestinal tract.
Mean Plasma Tofacitinib Concentration
Biora Therapeutics Achieves Positive Interim Results for Clinical Trial of BT-600, Advancing NaviCap™ Platform Development
April 04, 2024 08:00 ET | Biora Therapeutics, Inc.
All pharmacokinetic endpoints were achieved; all NaviCap™ devices performed as intended; no safety signals observed
Biora-tm_rgb.jpg
Biora Therapeutics Announces Closing of $6 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
April 03, 2024 16:05 ET | Biora Therapeutics, Inc.
SAN DIEGO, April 03, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced the closing of its previously...
Biora-tm_rgb.jpg
Biora Therapeutics Announces $6 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
April 01, 2024 08:00 ET | Biora Therapeutics, Inc.
Biora has entered into definitive agreements for the purchase and sale of 5,454,548 shares of common stock.
Biora-tm_rgb.jpg
Biora Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results
March 26, 2024 16:05 ET | Biora Therapeutics, Inc.
All performance targets achieved in single-ascending dose (SAD) cohorts of BT-600 clinical trial. Management to host conference call today at 4:30 PM ET.
Biora-tm_rgb.jpg
Biora Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update
March 18, 2024 08:00 ET | Biora Therapeutics, Inc.
Biora's management will host a webcast and conference call on Tuesday, March 26, 2024, after the close of financial markets.
Biora-tm_rgb.jpg
Biora Therapeutics Further Reduces Net Debt and Monetizes Legacy Asset
March 11, 2024 08:00 ET | Biora Therapeutics, Inc.
Monetization of legacy asset brings in $3 million in nondilutive capital; note exchange brings in another $2.8 million in capital, reduces net debt